Abstract
The primary aim of our analysis was to do a systemic review and updated meta-analysis of literature published in the last 10 years and look for the association of neoadjuvant chemoradiation and risk of subsequent clinically significant pancreatic fistula. EMBASE, MEDLINE, and the Cochrane Database were searched for. Studies comparing outcomes in patients receiving neoadjuvant chemoradiotherapy first with those patients who received surgery first in case of pancreatic cancer. A systemic review and Metanalysis were done according to MOOSE and PRISMA guidelines. Heterogeneity was measured using Q tests and I2, and p < 0.10 was determined as significant. Twenty-six studies including 17,021 patients finally included in the analysis. 339 patients out of a total of 3,386 developed clinically significant pancreatic fistula in the neoadjuvant first group. 2,342 patients out of 13,335 patients developed clinically significant pancreatic fistula in the surgery first group. Neoadjuvant treatment significantly reduced the risk of subsequent clinically significant pancreatic fistula (p ≤ 0.0001). The number of patients with soft pancreas was significantly higher in the surgery first group (p < 0.0001). Pancreatic duct diameter mentioned in only two studies but there was no significant difference between both groups (p = 1). Blood loss was significantly more in the surgery first group (p < 0.0001). There was no difference in pancreaticoduodenectomy or distal pancreatectomy performed between both groups (p = 0.82). Neoadjuvant treatments may be responsible for the lower rates of clinically significant pancreatic fistula after subsequent surgery.
Highlights
Pancreatic fistula is one of the main complications after pancreatic surgery and the leading cause of morbidity and mortality after pancreatic surgery
There was no difference in the number of borderline resectable pancreatic tumors between both groups. (p= 0.34)
Neoadjuvant treatments may be responsible for the lower rates of clinically significant pancreatic fistula after subsequent surgery
Summary
Pancreatic fistula is one of the main complications after pancreatic surgery and the leading cause of morbidity and mortality after pancreatic surgery. When a tumor invades the superior mesenteric vein or superior mesenteric artery it is sometimes difficult to achieve R0 resection, which can hamper chances of long-term survival. These tumors are defined as borderline resectable tumors. [5,6,7] Consensus definition of borderline resectable pancreatic cancer includes anatomical considerations(contact with
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.